Ophthalmic Devices Panel Supports Safety For Ocular Therapeutix’ ReSure Sealant, But Other Votes Mixed
This article was originally published in The Gray Sheet
Executive Summary
The FDA panel voted 9-1 in favor of the safety of Ocular’s PMA Sept. 19, but 5-1 on whether the benefits of the device, an in situ-formed hydrogel that creates an adherent temporary, soft and lubricious sealant to prevent leakage from clear corneal incisions, outweigh its risk, and 5-3 on its effectiveness. Multiple panelists abstained from the last two votes based on concerns with wording of the indication.
You may also be interested in...
New Product Briefs: ReSure Sealant, Direct Flow TAVR; DePuy Spine Device
Ocular Therapeutix’s ReSure Sealant gains PMA approval for sealing cataract surgery incisions. Direct Flow gains CE mark for larger version of its repositionable transcatheter aortic valve replacement. More product news.
News In Brief
Industry urges restraint at 510(k) modifications meeting. User fee sequestration unaddressed at House Appropriations Committee markup. More news
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.